Robert LaCaze
Executive Vice President, Oncology Strategic Business Unit
Executive Vice President, Oncology Strategic Business Unit
Robert joined Bayer as SVP, Head of Oncology TA in October 2015. He has more than 27 years of bio-pharmaceutical experiences most of which has been spent in specialty areas, mainly Oncology. Before joining Bayer, Robert was the SVP, Global Oncology with Bristol-Myers Squibb and co-led the Oncology Disease Strategy team with direct responsible to set the vision, strategy, and execution for the Immuno-Oncology (I-O) Franchise at BMS.
Robert currently serves on the Louisiana Tech College of Business Administration Advisory Board and is a member of AACR and BioNJ. He, his wife and two sons reside in Robbinsville, New Jersey.
CEO Cancer Gold Standard™
Gold Standard Employer
Since 2014
Quote
Bayer HealthCare is committed to delivering Science For A Better Life by advancing a portfolio of innovative treatments that offer meaningful progress to doctors and patients battling the toughest cancers. The Gold Standard recognition by the CEO Roundtable on Cancer underscores our commitment to fighting cancer, through our Oncology portfolio and ongoing efforts to provide employees with the education and healthcare they need to be as healthy as possible.
Life Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Bhavesh Ashar; Senior Vice President and Head, Oncology; Chandra Ramanathan PHD MBA, Vice President and Head, East Coast Innovation Center; Robert LaCaze, Executive VP, Oncology Strategic Business Uni; Svetlana Kobina MD PhD
Project Data Sphere, LLC
Data Provider
Since 2014
Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products for diagnosing, preventing, and treating diseases for human health. The company focuses on women's healthcare, diagnostic imaging, general medicine, hematology/neurology, and oncology products. It provides NEXAVAR, an anticancer medicine used to treat kidney cancer; Stivarga regorafenib tablets for the treatment of patients with metastatic colorectal cancer; Aflibercept (Eylea), an anti-angiogenic therapy for wAMD patients; Xofigo (radium Ra 223 dichloride), an alpha particle-emitting radioactive therapeutic agent for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and visceral metastatic diseases; Gadavist, a gadolinium-based contrast agent for pediatric patients; and Dienogest to treat endometriosis in women. Bayer HealthCare Pharmaceuticals Inc. has a strategic alliance with Broad Institute. The company was founded in 1979 and is headquartered in Wayne, New Jersey. Bayer HealthCare Pharmaceuticals Inc. operates as a subsidiary of Bayer AG.